The toxicity of methyl isocyanate: Where do we stand?

The toxicity of methyl isocyanate: Where do we stand?

Background: The extent to which clinical and non-clinical factors impact on the waiting-list prioritization preferences of patients in the queue is unknown. Using a series of hypothetical scenarios, the objective of this study was to examine the extent to which clinical and non-clinical factors impacted on how patients would prioritize others relative to themselves in the coronary artery bypass...

The Battle Against COVID-19: Where Do We Stand Now?

Bhopal methyl isocyanate affected population and cancer susceptibility: where do we stand now?

Further to our recent publications on cancer morbidity of Methyl isocyanate (MIC) exposed long-term survivors and their offspring and carcinogenesis of MIC in this journal (Senthilkumar et al., 2011; 2012), my attention was drawn to express my views to Indian Council of Medical Research (ICMR) for the need to validate MIC in cancer etiology, in particular, to cancer risk prediction in the prese...

Clinical Pharmacy in Iran: Where Do We Stand?

Since late 1960s, pharmacists in the USA and England have started a professional movement towards a more efficient presence in clinical wards of hospitals. A similar movement has started in developed European countries during the past decade. Pharmacists are convinced of the need for them to play their role as drug consultants and pharmacotherapy advisers to make decisions on drug therapy probl...

Clinical Pharmacy in Iran: Where Do We Stand?

Since late 1960s, pharmacists in the USA and England have started a professional movement towards a more efficient presence in clinical wards of hospitals. A similar movement has started in developed European countries during the past decade. Pharmacists are convinced of the need for them to play their role as drug consultants and pharmacotherapy advisers to make decisions on drug therapy probl...